Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis

Table 3 Meta-analysis of hepatitis B virus infection and clinicopathological features

Clinicopathological features	n	Cases	Analytical model	OR	95%CI	Heterogeneity
						I2(%)	P value
Gender (male vs female)	4	677	REM	1.91	1.06-3.44	55.0	0.084
ALT (≥ 42 U/L vs < 42 U/L)	3	610	REM	1.23	0.64-2.35	63.3	0.066
AST (≥ 37 U/L vs < 37 U/L)	3	610	REM	1.93	1.11-3.35	52.8	0.120
TBIL(≥ 20 μmol/L vs < 20 μmol/L)	3	610	FEM	0.91	0.62-1.33	0.00	0.979
γ-GT (≥ 64 U/L vs < 64 U/L)	3	610	REM	0.77	0.43-1.38	61.7	0.074
AFP (≥ 20 ng/mL vs < 20 ng/mL)	4	669	FEM	3.86	2.58-5.78	0.00	0.804
CA19-9 (≥ 37 U/mL vs < 37 U/mL)	4	668	FEM	0.47	0.34-0.65	0.00	0.806
Cirrhosis (yes vs no)	4	672	FEM	6.44	4.33-9.56	38.8	0.179
Capsule formation (yes vs no)	4	672	FEM	6.04	3.56-10.26	31.9	0.221
Differentiation (well/moderate vs poor)	4	672	REM	0.86	0.41-1.80	73.5	0.010
Tumor location (both lobes vs one lobe)	3	534	FEM	0.76	0.31-1.87	0.00	0.995
Tumor number (multiple vs single)	4	672	FEM	0.91	0.57-1.46	0.00	0.983
Tumor size (≥ 5 cm vs < 5 cm)	3	355	FEM	0.72	0.46-1.14	37.9	0.200
Lymph node metastasis (yes vs no)	4	672	FEM	0.39	0.25-0.58	0.00	0.990
Vascular invasion(yes vs no)	4	672	REM	1.10	0.49-2.43	69.0	0.021

FEM: Fixed-effects model; REM: Random-effects model; OR: Odds ratio; CI: Confidence interval; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; γ-GT: γ-glutamyl transpeptidase; AFP: Alpha fetoprotein; CA19-9: Carbohydrate antigen 19-9.